晚期皮肤T细胞淋巴瘤中STAT6调控基因的全基因组转录组分析
本研究通过全基因组表达谱分析与药物抑制STAT6相结合,鉴定了蕈样肉芽肿(MF)和塞扎里综合征(SS)肿瘤中STAT6调控的基因。STAT6调控细胞周期进程、基因组稳定性及Th2细胞因子产生的多条共同通路;抑制STAT6活化可下调细胞因子产生并诱导细胞周期阻滞,抑制恶性淋巴细胞增殖而不影响其存活。STAT6还通过上调免疫抑制、趋化及肿瘤基质重塑相关基因,促进晚期MF肿瘤微环境中肿瘤相关巨噬细胞的促肿瘤M2样表型。
要点
- STAT6在MF/SS恶性淋巴细胞中组成性活化,调控细胞周期进程、基因组稳定性及Th2细胞因子产生。
- 抑制STAT6活化可下调细胞因子产生并诱导细胞周期阻滞,抑制MF/SS恶性淋巴细胞增殖但不影响存活。
- STAT6通过上调免疫抑制、趋化及肿瘤基质重塑相关基因,促进肿瘤相关巨噬细胞的促肿瘤M2样表型。
核心结论
- STAT6是MF/SS发病和进展的主要因素,促进恶性淋巴细胞增殖和侵袭,同时诱导抗肿瘤免疫应答进行性抑制。
- 研究结果为疾病发病机制提供了新见解,并为治疗干预提供了新的前瞻性靶点。
研究设计与样本
- 研究结合全基因组表达谱分析与药物抑制STAT6,鉴定MF/SS肿瘤中STAT6调控的基因。
- 使用 cutaneous MF 肿瘤的离体皮肤外植体及SS患者外周血来源的Sezary细胞进行体外实验。
主要发现
- STAT6调控MF/SS恶性淋巴细胞中与细胞周期进程控制、基因组稳定性及Th2细胞因子产生相关的多条共同通路。
- 抑制STAT6活化可下调细胞因子产生并诱导细胞周期阻滞,抑制MF/SS恶性淋巴细胞增殖但不影响其存活。
- STAT6通过上调免疫抑制、趋化及肿瘤基质重塑相关基因,促进晚期MF肿瘤微环境中肿瘤相关巨噬细胞的促肿瘤M2样表型。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The signal transducer and activator of transcription 6 (STAT6) is a critical up-stream mediator of interleukin-13 (IL-13) and IL-4 signaling and is constitutively activated in malignant lymphocytes from Sezary syndrome (SS) and mycosis fungoides (MF), the most common subtypes of cutaneous T-cell lymphomas. By combining genome-wide expression profiling with pharmacological STAT6 inhibition, we have identified the genes regulated by STAT6 in MF/SS tumors. We found that STAT6 regulates several common pathways in MF/SS malignant lymphocytes that are associated with control of cell-cycle progression and genomic stability as well as production of Th2 cytokines. Using ex vivo skin explants from cutaneous MF tumors as well as Sezary cells derived from the blood of SS patients, we demonstrated that inhibition of STAT6 activation downregulates cytokine production and induces cell-cycle arrest in MF/SS malignant lymphocytes, inhibiting their proliferation but not their survival. Furthermore, we show that STAT6 promotes the protumoral M2-like phenotype of tumor-associated macrophages in the tumor microenvironment of advanced stage MF by upregulating the expression of genes associated with immunosuppression, chemotaxis, and tumor matrix remodeling. Thus, we show STAT6 to be a major factor in the pathogenesis and progression of MF/SS, promoting proliferation and invasion of the malignant lymphocytes while inducing a progressive depression of the antitumor immune response. Together, our results provide new insights into disease pathogenesis and offer new prospective targets for therapeutic intervention.
引用
- Gaydosik AM, Queen DS, Trager MH, et al. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood. 2020. PMID: 32438399. doi:10.1182/blood.2019004725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。